Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells

Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells

(2016) Naoko Mise et al.   CANCER SCIENCE

Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression

(2014) Ryuichi Sugamata et al.   JOURNAL OF ANTIBIOTICS

Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

(2014) W.-S. Chang et al.   JOURNAL OF IMMUNOLOGY

Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis

(2014) Amar Singh et al.   TUBERCULOSIS

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Dysfunction of Natural Killer T Cells in Patients with Active Mycobacterium tuberculosis Infection

(2012) Seung-Jung Kee et al.   INFECTION AND IMMUNITY

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model

(2011) Kevin Durgan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer

(2011) Shinichiro Motohashi et al.   CLINICAL IMMUNOLOGY

Immune microenvironments in solid tumors: new targets for therapy

(2011) S. L. Shiao et al.   GENES & DEVELOPMENT

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

Invariant natural killer T cell-based immunotherapy for cancer

(2010) Shinichiro Motohashi et al.   Immunotherapy

Regulatory T cells in tumor immunity

(2010) Hiroyoshi Nishikawa et al.   INTERNATIONAL JOURNAL OF CANCER

Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection

(2009) Markus Moll et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: CD28 Engagement Releases Antigen-Activated Invariant NKT Cells from the Inhibitory Effects of PD-1

(2009) J. Wang et al.   JOURNAL OF IMMUNOLOGY

PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells

(2009) V. V. Parekh et al.   JOURNAL OF IMMUNOLOGY

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

(2009) O Akbari et al.   Mucosal Immunology

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvant activity mediated by iNKT cells

(2009) Shinichiro Fujii et al.   SEMINARS IN IMMUNOLOGY

Clinical applications of natural killer T cell–based immunotherapy for cancer

(2008) Shinichiro Motohashi et al.   CANCER SCIENCE